Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient

Abstract Background The compound letermovir (LMV) has recently been approved for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant. LMV inhibits CMV replication by binding to the viral terminase com...

Full description

Bibliographic Details
Main Authors: Susanne Jung, Manuela Michel, Thomas Stamminger, Detlef Michel
Format: Article
Language:English
Published: BMC 2019-05-01
Series:BMC Infectious Diseases
Subjects:
Antiviral resistance
Cytomegalovirus
Letermovir
Genotyping
Allogenic hematopoietic-cell transplantation
Acute myeloid leukemia
Online Access:http://link.springer.com/article/10.1186/s12879-019-4016-1

Internet

http://link.springer.com/article/10.1186/s12879-019-4016-1

Similar Items